Microbicides 2004 Microbicides 200428-31 March 2004, Hilton London MetropoleThe conference42 million men, women and children worldwide were living with HIV by the end of December 2002 (source: UNAIDS), including five million newly-infected during that year alone. Another 45 million people will become infected between 2002 and 2010, unless the current transmission rates can be vastly reduced. Of the 42 million, 29.4 million live in sub-Saharan Africa and 58% of them are women. Not only are women more susceptible to HIV infection, many are powerless to insist on the use of condoms or other methods of protecting themselves. In this context, and with the knowledge that an effective HIV vaccine is unlikely to be available for several years, the need for an effective topical microbicide grows ever more urgent. 2004 should prove to be a landmark year in the field of microbicide development as the first Phase III trials of novel products are due to start – the next step along the road to making a microbicide available to the millions worldwide in desperate need of protection.The aims of the Microbicides 2004 conference are to:Report novel or innovative work in the microbicides fieldProvide updates on recent microbicides research, divided into three tracks: basic science, clinical science, and behavioural science (including public health and the microbicide marketplace)Provide a forum for the discussion of new developments in microbicide research including ethical, clinical, behavioural and methodological issuesPresent opportunities for knowledge-sharing between microbicide researchers, public-health workers and advocacy organisations.There will be an opening ceremony on the evening of Sunday 28 March at which politicians, policy makers and the international media are expected. The conference will run for a full three days, each of which will contain:Scientific overviews and presentations with plenary sessions, invited lecturers and presentations of original researchWorkshops to review issues unique to microbicides such as trial design and outcome measures, and ethical issues in the clinical trials of microbicidesPoster sessions. Focus on LondonFollowing the successful Microbicides conferences in Washington in 2000 and Antwerp in 2002, March 2004 sees the focus move to London.The venue is the Hilton Metropole Hotel, two minutes by taxi from Paddington station and the Heathrow Express, with a journey time from the airport of 15 minutes. The hotel is in walking distance of Hyde Park and London’s main shopping streets, and close to Imperial College. Accommodation will be available at the venue and other hotels in the vicinity.London in March offers a variety of diversions for out-of-conference relaxation, including sight-seeing and shopping; the arts and the theatre; and pubs, clubs and restaurants to suit every taste. Conference staff will be on hand to help delegates plan their spare time.To book your place or find out more information, e-mail info@microbicides2004.org.uk or telephone the Event Office on +44 (0) 20 7720 4411
Oral: invited speaker Oral: Track A Oral: Track B Oral: Track C Poster: Track A Poster: Track B Poster: Track C Abstract only Authors

02508 CELLULOSE ACETATE PHTHALATE INHIBITS HIV-1 INFECTION VIA DIFFERENT CLADES IN CELLULAR, DENDRITIC CELL AND HUMAN CERVICAL EXPLANT MODELS

Wallace, Greg*
Jiang, S**, Watts, P*, Strick, N*, Griffin, G*, Neurath, A R** and Shattock R J*
*St Georges Hospital Medical School, London UK and **The Lindsay F Kimball Research Institute of the New York Blood Center, New York, NY, USA

HIV-1 and a number of other STD’s with a long history of safe usage in humans. We have investigated CAP as a potential microbicide both as a base compound and a formulated gel against a range of HIV-1 strains and clades using cellular and human cervical explant models and in combination with zinc finger inhibitors.

Methods
Anti-HIV-1 activity of CAP and nucleocapsid p7 zinc finger inhibitors (zfi) alone and in combination was determined by in vitro assays and in ex vivo human cervical explant models. THP-1/DC-SIGN transfectants and monocyte derived dendritic cells were used to investigate the action of CAP against dendritic cell medicated infection. Biocompatibility was assessed by viability assays and cytokine profiles from mucosal tissue exposed to both compounds and N-9 as a control.

Results
Our results show that CAP strongly inhibits the activity of a number of different cell free and cell associated strains and clades of HIV-1. It inhibits viral transfer via DC-SIGN and by migratory cells emigrating from cervical explants. Furthermore, it is biocompatible and is effective in the presence of seminal plasma and across a wide pH range. Preliminary studies with zfi showed some promise for development of a combination microbicide.

Conclusions
CAP has shown strong anti-viral activity across a spectrum of HIV strains and clades in cellular, dendritic cell and cervical explant models and is biocompatible at all concentrations tested. Therefore, it shows good potential for development as a topical microbicide.

Mr Gregory Wallace
St Georges Hospital Medical School, Dept of Infectious Diseases, Cranmer Terrace, London SW17 0RE
(Tel) 020 8725 1603 (Fax) 020 8725 3487 (E-mail) gwallace@sghms.ac.uk